You are here

Amgen

Expecting hostile suitors, Shire brings in reinforcements

Fierce Pharma

Wed, 06/18/14 - 05:31 am

Bristol-Myers Squibb

Gilead Sciences

3 Undervalued Amgen Growth Opportunities to Watch

Motley Fool

Mon, 06/16/14 - 09:03 pm

What Will Happen When Biotech Drugs Go Generic?

Forbes

Fri, 06/13/14 - 10:58 am

Bristol-Myers Squibb

Amgen psoriatic arthritis drug maintains efficacy after 1 yr -study

Yahoo/Reuters

Wed, 06/11/14 - 05:31 pm

psoriatic arthritis

FirstWord List: Top 15 pharma and lead product dependency

First Word Pharma

Mon, 06/9/14 - 10:35 am

Boehringer Ingelheim

Bristol-Myers Squibb

Amgen abruptly puts 70 employees on paid leave

InsuranceNewsNet.com

Fri, 06/6/14 - 10:50 am

2 Reasons to Watch Amgen

Motley Fool

Thu, 06/5/14 - 10:55 pm

Time to Break Up Amgen?

Barron's

Wed, 06/4/14 - 02:55 pm

ASCO 2014: Doubling Down on Next-Gen Cancer Drugs

Motley Fool

Tue, 06/3/14 - 12:26 pm

biospecific antibodies

Teva acquisition a positive for Amgen, says Piper Jaffray

Yahoo/Fly on the Wall

Tue, 06/3/14 - 10:51 am

Teva Pharmaceuticals

New Detailed Phase 3 Data Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With A Rare And Serious Genetic Disorder That Causes High Cholesterol

Yahoo/PR NewsWire

Sun, 06/1/14 - 11:57 am

hypercholesterolemia

Amgen Highlights Phase 2 Results Of Vectibix Versus bevacizumab In Combination With FOLFOX In Patients With Wild-Type RAS (KRAS And NRAS) Metastatic Colorectal Cancer

Yahoo/PR NewsWire

Sat, 05/31/14 - 10:07 am

colorectal cancer

Amgen gets expanded approval for colon cancer drug

Yahoo/AP

Sat, 05/24/14 - 09:49 am

3 Biotech Dividend Darlings for Your Portfolio

Motley Fool

Sat, 05/17/14 - 09:56 am

Teva Pharmaceuticals

Think Like A Brain Surgeon: Dr. Christopher James Offers Fresh Perspectives On 6 Exciting Biotechs

Seeking Alpha

Fri, 05/16/14 - 08:20 am

Corcept Therapeutics

Ligand Pharmaceuticals

Amgen announces publication of data from Phase 3 LAPLACE-2 study of evolocumab

The Fly on the Wall

Tue, 05/13/14 - 10:21 pm

What's Hurting Biotechnology Stocks?

Seeking Alpha

Tue, 05/13/14 - 11:37 am

Gilead Sciences

This Week in Biotech: Chelsea Therapeutics Finds a Buyer While Corcept Implodes

Motley Fool

Sat, 05/10/14 - 12:45 pm

Chelsea Therapeutics

Corcept Therapeutics

Amgen, AstraZeneca reports brodalumab study met primary, secondary endpoints

The Fly on the Wall

Sat, 05/10/14 - 10:48 am

New Melanoma Therapies Are Ready For Primetime: Sanjiv Agarwala

Seeking Alpha

Wed, 04/30/14 - 12:50 pm

Bristol-Myers Squibb

Pages